[Federal Register Volume 79, Number 178 (Monday, September 15, 2014)]
[Notices]
[Page 54987]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2014-21855]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive Evaluation License: Development of
Antibody-Drug Conjugates Comprising Topoisomerase Inhibitors for the
Treatment of Human Cancers
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This is notice, in accordance with 35 U.S.C. 209 and 37 CFR
part 404, that the National Institutes of Health, Department of Health
and Human Services, is contemplating the grant of an exclusive license
to practice the inventions embodied in U.S. Provisional Patent
Application No. 60/844,027 entitled, ``Azonafide derived tumor and
cancer targeting compounds,'' filed September 12, 2006 [HHS Ref. No. E-
160-2006/0-US-01], PCT Application No. PCT/US2007/078233 entitled,
``Azonafide derived tumor and cancer targeting compounds,'' filed
September 12, 2007 [HHS Ref. No. E-160-2006/0-PCT-02], European Patent
Application No. 7842310.0 entitled, ``Azonafide derived tumor and
cancer targeting compounds,'' filed September 12, 2007 [HHS Ref. No. E-
160-2006/0-EP-03], and U.S. Patent Application No. 12/441,029 entitled,
``Azonafide derived tumor and cancer targeting compounds,'' filed March
12, 2009 now US Patent No. 8,008,316 issued August 30, 2011 [HHS Ref.
No. E-160-2006/0-US-04], and all related continuing and foreign
patents/patent applications for the technology family, to Oncolinx,
Inc. The patent rights in these inventions have been assigned to the
Government of the United States of America.
The prospective exclusive evaluation option license territory may
be worldwide and the field of use may be limited to the development and
use of the licensed patent rights as a component of an antibody-drug
conjugate for the treatment of human cancers. Upon expiration or
termination of the exclusive evaluation option license, Oncolinx will
have the right to execute an exclusive patent commercialization license
which will supersede and replace the exclusive evaluation option
license with no broader territory than granted in the exclusive
evaluation option license and the field of use will be commensurate
with the commercial development plan at the time of conversion.
DATES: Only written comments and/or applications for a license which
are received by the NIH Office of Technology Transfer on or before
September 30, 2014 will be considered.
ADDRESSES: Requests for copies of the patent applications, inquiries,
comments, and other materials relating to the contemplated exclusive
evaluation option license should be directed to: Jennifer Wong, M.S.,
Senior Licensing and Patenting Manager, Office of Technology Transfer,
National Institutes of Health, 6011 Executive Boulevard, Suite 325,
Rockville, MD 20852-3804; Telephone: (301) 435-4633; Facsimile: (301)
402-0220; Email: [email protected].
SUPPLEMENTARY INFORMATION: The present technology provides compound
formulation and method of use of improved derivatives of 2-[2'-(2-
aminoethyl)-2-methyl-ethyl]-l,2-dihydro-6-methoxy-3H-dibenz-
[de,h]isoquinoline-l,3-dione (herein referred to as azonafides),
anthracene-based DNA intercalcators that inhibit tumor growth. The
synthesized azonafides can be attached to a ligand or antibody to
recognize specific receptors on cancer cells and delivered as a
targeted cytotoxic payload. The azonafides have been developed to allow
for easy modification with different peptide linkers and antibodies,
but also allow for rapid release once cleaved in lysosomes after
delivery to the cancer cell enabling highly targeted attack of cancer
cells. The azonafides have reduced toxicity and lower development of
drug resistance.
The prospective exclusive evaluation option license is being
considered under the small business initiative launched on October 1,
2011 and will comply with the terms and conditions of 35 U.S.C. 209 and
37 CFR part 404. The prospective exclusive evaluation option license,
and a subsequent exclusive patent commercialization license, may be
granted unless within fifteen (15) days from the date of this published
notice, the NIH receives written evidence and argument that establishes
that the grant of the license would not be consistent with the
requirements of 35 U.S.C. 209 and 37 CFR part 404.
Any additional, properly filed, and complete applications for a
license in the field of use filed in response to this notice will be
treated as objections to the grant of the contemplated exclusive
evaluation option license. Comments and objections submitted to this
notice will not be made available for public inspection and, to the
extent permitted by law, will not be released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: September 9, 2014.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 2014-21855 Filed 9-12-14; 8:45 am]
BILLING CODE 4140-01-P